Sygnomics is a personalized precision oncology startup that helps oncologists improve patient outcomes by accurately predicting each patient’s risk of disease progression and identifying specific therapies that could be effective against their cancer. Unlike current mutation-focused genetic testing reports, Sygnomics’ lab-developed test report is based on specific disease pathways driving the patient’s cancer, identified by patented systems biology-based network analysis of their tumor’s multi-omics profile. As Sygnomics accumulates patient insights, it will work with pharmaceutical companies to develop biomarkers to stratify patients that may benefit from a drug, and get other drugs rapidly approved for new indications.